Metastatic Bladder Cancer:: A Review of Current Management

Andrew Fletcher; Ananya Choudhury; Nooreen Alam

doi:10.5402/2011/545241

Metastatic Bladder Cancer: A Review of Current Management

Andrew Fletcher, Ananya Choudhury, Nooreen Alam

Division of Cancer Sciences (L5)

The Christie Hospital NHS Foundation Trust

Research output: Contribution to journal › Review article › peer-review

Abstract

Bladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies.

Original language	English
Pages (from-to)	1-8
Journal	ISRN Urology
Volume	2011
DOIs	https://doi.org/10.5402/2011/545241
Publication status	Published - 1 Jan 2011

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5402/2011/545241

https://www.hindawi.com/archive/2011/545241/

Cite this

@article{cafde24e10f34f21b8abd5ce28bf3231,

title = "Metastatic Bladder Cancer:: A Review of Current Management",

abstract = "Bladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies.",

author = "Andrew Fletcher and Ananya Choudhury and Nooreen Alam",

year = "2011",

month = jan,

day = "1",

doi = "10.5402/2011/545241",

language = "English",

volume = "2011",

pages = "1--8",

journal = "ISRN Urology",

issn = "2090-5807",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Metastatic Bladder Cancer:

T2 - A Review of Current Management

AU - Fletcher, Andrew

AU - Choudhury, Ananya

AU - Alam, Nooreen

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Bladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies.

AB - Bladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies.

U2 - 10.5402/2011/545241

DO - 10.5402/2011/545241

M3 - Review article

SN - 2090-5807

VL - 2011

SP - 1

EP - 8

JO - ISRN Urology

JF - ISRN Urology